CytoMed Therapeutics (FRA:F98) Accounts Payable: €0.08 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:F98 CytoMed Therapeutics Ltd FRA:F98
19 GF Score
Price €0.76
! 2 Warning Signs
View Full Analysis

What is CytoMed Therapeutics Accounts Payable?

CytoMed Therapeutics FRA:F98 -9.58% 19 Accounts Payable is €0.08 Mil as of Dec. 2025. GuruFocus rates FRA:F98 with a GF Score™ of 19/100. The stock has 2 warning signs investors should review.

CytoMed Therapeutics's Accounts Payable for the quarter that ended in Dec. 2025 was €0.08 Mil.

CytoMed Therapeutics's quarterly Accounts Payable increased from Dec. 2024 (€0.03 Mil) to Jun. 2025 (€0.06 Mil) and increased from Jun. 2025 (€0.06 Mil) to Dec. 2025 (€0.08 Mil).

CytoMed Therapeutics's annual Accounts Payable increased from Dec. 2023 (€0.02 Mil) to Dec. 2024 (€0.03 Mil) and increased from Dec. 2024 (€0.03 Mil) to Dec. 2025 (€0.08 Mil).

CytoMed Therapeutics Accounts Payable Related Terms

CytoMed Therapeutics Accounts Payable Historical Data

* Premium members only.

The historical data trend for CytoMed Therapeutics's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CytoMed Therapeutics Accounts Payable Chart

CytoMed Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Accounts Payable
Get a 7-Day Free Trial 0.03 0.01 0.02 0.03 0.08

CytoMed Therapeutics Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 0.02 0.03 0.03 0.06 0.08
FRA:F98
19GF Score
CytoMed Therapeutics Ltd FRA:F98
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CytoMed Therapeutics Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of €0.08 Mil mean?
CytoMed Therapeutics (FRA:F98) has a Accounts Payable of €0.08 Mil as of Dec. 2025. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on CytoMed Therapeutics and its competitors.
Is CytoMed Therapeutics' Accounts Payable too high?
CytoMed Therapeutics' current Accounts Payable is €0.08 Mil. Overall, CytoMed Therapeutics has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does CytoMed Therapeutics' Accounts Payable compare to LEXX and INAB?
CytoMed Therapeutics' Accounts Payable of €0.08 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Biotechnology company?
A good Accounts Payable depends on the Biotechnology industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on CytoMed Therapeutics and its competitors. CytoMed Therapeutics's current Accounts Payable is €0.08 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CytoMed Therapeutics stock overvalued right now?
CytoMed Therapeutics (FRA:F98) has a current Accounts Payable of €0.08 Mil. The current Accounts Payable is €0.08 Mil. CytoMed Therapeutics' overall GF Score™ is 19/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For CytoMed Therapeutics (FRA:F98), the current Accounts Payable is €0.08 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CytoMed Therapeutics Business Description

Other Exchanges GDTC:USA
Address 1 Commonwealth Lane, No. 08-22 One Commonwealth, Singapore, SGP, 149544
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.
19GF Score

Get the complete analysis for FRA:F98

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.76
Price